PA007618.m1:In Vivo Grade Recombinant Anti-human MHC Class II HLA-DP/DQ/DR Monoclonal Antibody (Clone: IVA12), Mouse IgG1 Kappa
Recombinant Mouse IgG1 Monoclonal Antibody.
Clone: IVA12.
Isotype: Mouse IgG1 Kappa.
Source:The anti-human MHC Class II HLA-DP/DQ/DR monoclonal antibody (clone: IVA12) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: IVA12) specifically binds to human MHC Class II HLA-DP/DQ/DR.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human MHC Class II HLA-DP/DQ/DR protein.
Form of Antibody: 0.2 uM fIItered solution, pH 7.4, no stabIIizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human MHC Class II HLA-DP/DQ/DR monoclonal antibody of clone IVA12 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
StabIIity & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human MHC Class II HLA-DP/DQ/DR antibody (IVA12):
MetE: a promising protective antigen for tuberculosis vaccine development
Almujri, S. S., et al. (2025). Front Immunol. 2025 Jul 21;16:1593263. doi: 10.3389/fimmu.2025.1593263. PMID: 40761798
The IVA12 antibody (anti-human MHC Class II HLA-DP/DQ/DR) was used alongside B721 (HLA-DP) and W6/32 (pan-HLA-I) for sequential immunoprecipitation to enrich HLA-DQ and HLA-DR molecules in an immunopeptidomics study. This approach identified metE as a protective TB vaccine candidate, demonstrating significant reduction in bacterial burden in vivo when formulated with AS01™ or AddaS03™ adjuvants in mouse challenge models.
Tags: anti-human MHC Class II HLA-DP/DQ/DR IVA12; anti-human MHC Class II HLA-DP/DQ/DR IVA12 mAb
HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses
Wang, M., et al. (2010). PLoS One. 2010 May 7;5(5):e10533. doi: 10.1371/journal.pone.0010533. PMID: 20479886
The IVA12 antibody (anti-human MHC Class II HLA-DP/DQ/DR, 10 µg/ml) blocked pan-HLA-II-restricted CD4+ T cell responses to influenza A virus peptides in ELISPOT assays, unlike W6/32 (anti-HLA-I), which had partial or no effect. Subtype-specific antibodies (anti-HLA-DR L243, anti-HLA-DQ SPV-L3, anti-HLA-DP B7/21) further confirmed that IVA12 inhibited IFNγ spot formation for 15 peptides, including four HLA-I nonbinders.
Tags: anti-human MHC Class II HLA-DP/DQ/DR IVA12 in vivo; anti-human MHC Class II HLA-DP/DQ/DR IVA12 mAb in vivo
Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion
Bandoh, S. A., et al. (1997). Clin Cancer Res. 1997 May;3(5):1037-44. doi: 10.1158/1078-0432.CCR-3-5-1037. PMID: 9166543
The IVA12 antibody (anti-human MHC Class II HLA-DP/DQ/DR) and L243 (anti-HLA-DR) inhibited IFNγ secretion by tumor-infiltrating lymphocytes (TILs) from three ovarian cancer patients, confirming MHC class II-restricted cytokine responses. TILs from patient 3, primarily CD4+, secreted IFNγ and TNFα upon autologous tumor stimulation, highlighting IVA12’s role in identifying class II-restricted T cell activity.
Tags: anti-human MHC Class II HLA-DP/DQ/DR IVA12 antibody in animal model; anti-human MHC Class II HLA-DP/DQ/DR IVA12 in cancer research
A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients
Cassotta, A., et al. (2019). Nat Med. 2019 Sep;25(9):1402-1407. doi: 10.1038/s41591-019-0568-2. PMID: 31501610
The IVA12 antibody (anti-human MHC Class II HLA-DP/DQ/DR) was used for MHC class II purification in immunopeptidomics to identify a dominant T cell epitope driving anti-drug antibody responses to natalizumab. In vivo immunogenicity was assessed in humanized mouse models, with epitope-specific T cells tracked to evaluate the immune response.
Tags: function of anti-human MHC Class II HLA-DP/DQ/DR IVA12; function of anti-human MHC Class II HLA-DP/DQ/DR IVA12 mAb
Immunopeptidomics for next-generation bacterial vaccine development
Mayer, R. L., et al. (2021). Trends Microbiol. 2021 Nov;29(11):1034-1045. doi: 10.1016/j.tim.2021.04.010. PMID: 34030969
The IVA12 antibody (anti-human MHC Class II HLA-DP/DQ/DR) enriched pan-HLA class II molecules in an immunopeptidomics workflow, enabling identification of bacterial antigens presented by MHC II. These antigens showed in vivo immunogenicity in mouse models, with vaccination protecting against bacterial challenge, highlighting IVA12’s utility in vaccine development.
Tags: anti-human MHC Class II HLA-DP/DQ/DR antibody IVA12; IVA12 anti-human MHC Class II HLA-DP/DQ/DR antibody
For more references about anti-human MHC Class II HLA-DP/DQ/DR antibody (IVA12), please contact our scientific support team with message@sydlabs.com.